NCT06251934View on ClinicalTrials.gov

Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma

CompletedOBSERVATIONAL
Enrollment

785

Participants

Timeline

Start Date

September 28, 2022

Primary Completion Date

November 1, 2022

Study Completion Date

November 24, 2022

Conditions
BRAF-positive Metastatic Melanoma
Trial Locations (1)

07936

Novartis, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY